These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31086780)

  • 1. Cognitive profile and determinants of poor cognition in people without dementia in Parkinson's disease.
    Barnish M; Daley DJ; Deane KH; Clark AB; Gray RJ; Horton SM; Butterfint ZR; Myint PK
    Med J Islam Repub Iran; 2019; 33():1. PubMed ID: 31086780
    [No Abstract]   [Full Text] [Related]  

  • 2. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
    Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment.
    Samat NA; Abdul Murad NA; Mohamad K; Abdul Razak MR; Mohamed Ibrahim N
    Front Neurosci; 2017; 11():712. PubMed ID: 29326545
    [No Abstract]   [Full Text] [Related]  

  • 4. Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson's disease.
    Almeida KJ; Carvalho LCLS; Monteiro THOH; Gonçalves PCJ; Campos-Sousa RN
    Dement Neuropsychol; 2019; 13(2):210-215. PubMed ID: 31285796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
    Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
    PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease.
    van Steenoven I; Aarsland D; Hurtig H; Chen-Plotkin A; Duda JE; Rick J; Chahine LM; Dahodwala N; Trojanowski JQ; Roalf DR; Moberg PJ; Weintraub D
    Mov Disord; 2014 Dec; 29(14):1809-15. PubMed ID: 25381961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease.
    Ozdilek B; Kenangil G
    Clin Neuropsychol; 2014; 28(2):333-43. PubMed ID: 24528299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease.
    Tumas V; Borges V; Ballalai-Ferraz H; Zabetian CP; Mata IF; Brito MMC; Foss MP; Novaretti N; Santos-Lobato BL
    Dement Neuropsychol; 2016; 10(4):333-338. PubMed ID: 29213478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
    Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
    Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Poston KL
    Parkinsonism Relat Disord; 2017 May; 38():31-34. PubMed ID: 28215728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.
    Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.
    Zadikoff C; Fox SH; Tang-Wai DF; Thomsen T; de Bie RM; Wadia P; Miyasaki J; Duff-Canning S; Lang AE; Marras C
    Mov Disord; 2008 Jan; 23(2):297-9. PubMed ID: 18044697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Quick Mild Cognitive Impairment (Qmci) screen to the Montreal Cognitive Assessment (MoCA) in an Australian geriatrics clinic.
    Clarnette R; O'Caoimh R; Antony DN; Svendrovski A; Molloy DW
    Int J Geriatr Psychiatry; 2017 Jun; 32(6):643-649. PubMed ID: 27427212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short Montreal Cognitive Assessment.
    Larner AJ
    J Geriatr Psychiatry Neurol; 2017 Mar; 30(2):104-108. PubMed ID: 28013571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures.
    Kim HM; Nazor C; Zabetian CP; Quinn JF; Chung KA; Hiller AL; Hu SC; Leverenz JB; Montine TJ; Edwards KL; Cholerton B
    Clin Park Relat Disord; 2019; 1():91-97. PubMed ID: 32368733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study.
    Biundo R; Weis L; Bostantjopoulou S; Stefanova E; Falup-Pecurariu C; Kramberger MG; Geurtsen GJ; Antonini A; Weintraub D; Aarsland D
    J Neural Transm (Vienna); 2016 Apr; 123(4):431-8. PubMed ID: 26852137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Mild Cognitive Impairment: Comparison of "MCI Specific" Screening Instruments.
    O'Caoimh R; Timmons S; Molloy DW
    J Alzheimers Dis; 2016; 51(2):619-29. PubMed ID: 26890758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort.
    Borland E; Nägga K; Nilsson PM; Minthon L; Nilsson ED; Palmqvist S
    J Alzheimers Dis; 2017; 59(3):893-901. PubMed ID: 28697562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Floor and ceiling effects on the Montreal Cognitive Assessment in patients with Parkinson's disease in Brazil.
    Koshimoto BHB; Brandão PRP; Borges V; Ferraz HB; Schumacher-Schuh AF; Rieder CRM; Olchik MR; Mata IF; Tumas V; Santos-Lobato BL
    Dement Neuropsychol; 2023; 17():e20230022. PubMed ID: 38053643
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.